Partial
Mostly Aligned
Patient Risk:
Moderate
Summary
Some statements align with labeling (mechanism as SGLT2 inhibition, need to assess renal function/volume status, risks of volume depletion/creatinine changes, genitourinary infections). However, multiple claims overgeneralize beyond the provided label excerpts (e.g., kidney “protection” phrased generally, creatinine rise described as “often” and creatinine-specific timing, dehydration/holding during illness not supported as stated, and a “monitoring before and after initiation” cadence is not explicitly specified). Several statements about kidney outcomes omit label limitations (e.g., specific populations and recommendations).
Category Scores
Accurate Statements
Farxiga belongs to the SGLT2 inhibitor class.
Label 12.1: 'Dapagliflozin is an inhibitor of SGLT2.'
SGLT2 inhibitors act through the kidneys’ glucose transport process.
Label 12.1: 'By inhibiting SGLT2, dapagliflozin reduces reabsorption of filtered glucose and thereby promotes urinary glucose excretion.'
Doctors monitor kidney-related laboratory results when patients take Farxiga.
Label 2.1 and 5.2: 'Assess renal function prior to initiation... and then as clinically indicated' and 'Monitor... renal function after initiating therapy.'
Farxiga can cause an initial small change in kidney laboratory values after starting.
Label 5.2: '...may sometimes manifest as symptomatic hypotension or acute transient changes in creatinine.'
Farxiga side effects may include low blood pressure and volume depletion.
Label 5.2: '...intravascular volume depletion... may sometimes manifest as symptomatic hypotension...'
Urinary or genital infections can be more common with SGLT2 inhibitors such as Farxiga.
Label 5.3: 'FARXIGA increases urinary glucose excretion... and increases the risk of genitourinary infections...'
Urinary or genital infections may require medical attention with Farxiga.
Label 5.3: 'Immediately evaluate... If suspected, discontinue FARXIGA and promptly institute appropriate medical and/or surgical intervention.' (supports need for prompt medical evaluation/treatment)
Acute kidney stress during severe vomiting, diarrhea, or inability to drink can occur with Farxiga.
Label 5.1: precipitating conditions for ketoacidosis include 'volume depletion' (illness can predispose to volume depletion); Label 5.2 includes acute transient creatinine changes and post-marketing reports of acute kidney injury in the context of volume depletion risk. (Label provided does not describe GI illness specifically for AKI, but supports risk via volume depletion.)
With SGLT2 inhibitors like Farxiga, kidney function often stabilizes.
No explicit statement in provided excerpts that kidney function 'often stabilizes' after initiation. (This is not directly supported by the provided label text.)
Farxiga belongs to the SGLT2 inhibitor class.
Label 12.1.
Farxiga reduces kidney disease progression in higher-risk groups.
Label 14.4: 'FARXIGA reduced the incidence of the primary composite endpoint of ≥50% sustained decline in eGFR, progression to ESKD...'
A clinician can decide whether to continue, adjust, or pause Farxiga temporarily.
Label 5.1 and 2.4 support temporary interruption/withholding in temporary clinical situations and around surgery; Label 5.2 supports monitoring and management. (The label does not use this exact phrasing, but it supports clinician-directed interruption in specific scenarios.)
Clinicians usually check kidney function before starting Farxiga and again after initiation.
Label 2.1 and 5.2: 'Assess renal function prior to initiation... and then as clinically indicated' and 'Monitor... renal function after initiating therapy.'
Unsupported Statements
Farxiga (dapagliflozin) is not generally known to damage kidneys.
Provided excerpts include acute transient creatinine changes and post-marketing reports of acute kidney injury (Label 5.2), which contradicts the framing of 'not generally known to damage kidneys.'
In major clinical trials, Farxiga has been associated with kidney protection.
Label excerpts support reduced incidence of kidney outcomes (e.g., sustained eGFR decline, ESKD) but do not use the term 'kidney protection' or general phrasing 'has been associated' without specifying endpoints/populations. Partially supported by Label 14.4, but not fully aligned as stated.
Any medication can affect kidney function in some patients.
Not stated in provided label excerpts.
The early change after starting Farxiga is often seen as an early rise in creatinine.
Label 5.2 mentions 'acute transient changes in creatinine' but does not specify frequency or that it 'is often seen' as an 'early rise.'
With SGLT2 inhibitors like Farxiga, kidney function often stabilizes.
No explicit support in provided excerpts.
With SGLT2 inhibitors like Farxiga, long-term outcomes can improve.
Label excerpts do show long-term outcome reductions in approved indications (e.g., CKD composite endpoint), but the statement is overly general and not tied to specific endpoints/populations as labeled.
People with more advanced chronic kidney disease (CKD) may be at higher risk for side effects that can indirectly worsen kidney function with Farxiga.
Label 5.2 indicates increased risk with impaired renal function (eGFR <60) but does not specifically attribute risk to 'more advanced CKD' phrased as a causal indirect worsening.
Older people may be at higher risk for side effects that can indirectly worsen kidney function with Farxiga.
Label 5.2 supports increased risk in elderly for volume depletion/hypotension/renal issues, but the statement is not explicitly framed as 'side effects that can indirectly worsen kidney function.'
People prone to dehydration may be at higher risk for side effects that can indirectly worsen kidney function with Farxiga.
Label 5.2 refers to patients on loop diuretics and volume depletion risk, but 'dehydration' and the 'indirectly worsen kidney function' phrasing is not explicitly stated.
Your prescriber may adjust guidance on hydration and when to hold Farxiga during illness.
Label 2.1 and 5.2 discuss correcting volume depletion before initiation and assessing volume status; Label 2.4 discusses surgery withholding. The provided excerpts do not state 'when to hold... during illness' broadly.
Dehydration or low blood pressure from increased urination, especially in people who already have low fluid intake or take diuretics, can mimic or contribute to kidney problems with Farxiga.
Label 5.2 supports risk of volume depletion and hypotension and monitoring renal function; it does not state 'mimic' kidney problems or 'especially low fluid intake' or 'from increased urination' as written.
Many SGLT2 inhibitors are temporarily paused during significant acute illness because of acute kidney stress risk.
Label excerpts provided only specify withholding for surgery/prolonged fasting (2.4) and withholding in situations that predispose to ketoacidosis (5.1). No general statement about pausing for acute illness to mitigate acute kidney stress.
Seek prompt medical advice for symptoms that could signal kidney trouble or severe dehydration such as feeling faint or very weak, persistent vomiting/diarrhea, very reduced urination, or sudden swelling.
The label excerpt includes monitoring for hypotension and renal function changes and evaluation for serious genitourinary infection, but it does not list these specific symptom examples (vomiting/diarrhea, reduced urination, sudden swelling) as 'kidney trouble' indicators.
Contact a clinician if routine lab monitoring shows a concerning change in kidney function while taking Farxiga.
The label supports monitoring renal function, but does not explicitly instruct patients to contact clinicians based on 'routine lab monitoring' changes in the way stated.
Farxiga reduces kidney disease progression in higher-risk groups.
Supported in principle (Label 14.4) but the statement omits that labeling specifies 'adults with chronic kidney disease at risk of progression' and specific endpoints; as written it is somewhat generalized.
For people with type 2 diabetes and kidney risk, Farxiga is often selected specifically because of kidney-related effects.
No support in labeling excerpts regarding selection practices or frequency.
Patients should not stop Farxiga on their own if creatinine rises.
Label excerpts do not contain patient-directed instructions about not stopping based on creatinine rise. They do discuss withholding/discontinuation in specific circumstances (e.g., ketoacidosis suspected, genitourinary infection suspected, and perioperative withholding).
Early lab changes can happen with Farxiga.
Partially supported by 'acute transient changes in creatinine' (5.2), but the statement is vague and may imply a general 'early lab changes' frequency. Not explicitly supported beyond the transient creatinine change concept.
The decision to continue, adjust, or pause Farxiga depends on how much kidney numbers changed, baseline kidney function, and whether there are signs of dehydration or illness.
Label supports assessing renal function and volume status, monitoring after initiation, and withholding in specific situations (ketoacidosis predisposition, surgery/prolonged fasting). It does not explicitly state a decision framework based on 'how much kidney numbers changed' or 'signs of dehydration or illness' as written.
Contradictions
Low
AI Statement
Farxiga (dapagliflozin) is not generally known to damage kidneys.
Label Reference
Label 5.2: 'There have been post-marketing reports of acute kidney injury... in patients receiving SGLT2 inhibitors, including FARXIGA.' (The provided label excerpts acknowledge acute kidney injury reports.)
Important Omissions
No mention of key limitations/indication-specific renal impairment boundaries (e.g., not recommended for glycemic control in T2DM with eGFR <45; initiation not recommended for CKD/hHF when eGFR <25 per provided excerpts).
Importance:
Moderate
No mention of contraindication (serious hypersensitivity to dapagliflozin/excipients).
Importance:
Moderate
No mention of diabetic ketoacidosis risk and guidance to discontinue/withhold in temporary clinical situations that predispose to ketoacidosis (including monitoring ketones and restarting criteria).
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Moderate
Generalizations and some unsupported phrasing could lead to miscalibrated expectations or management. However, multiple statements do reflect real labeled risks (volume depletion/creatinine changes, genitourinary infections) and labeled monitoring concepts. Omitted label elements (e.g., specific eGFR limitations, DKA guidance, contraindication) prevent fully accurate safety counseling.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Low |
Recommendation
Mostly Aligned
Primary Issue
Overgeneralized or partially unsupported statements (kidney protection language, frequency/timing of creatinine rise, illness-holding guidance) and omission of key labeled limitations and safety guidance.
Suggested Improvement
Rephrase statements to align with label text: specify labeled indications/endpoints for CKD outcomes, avoid frequency claims not in the label (e.g., 'often seen'), replace generalized illness-holding guidance with label-supported withholding scenarios (e.g., surgery/prolonged fasting; ketoacidosis predisposition), and include key labeled renal function limitations (eGFR thresholds) and the DKA/contraindication essentials when discussing safety.